Event Detail

e-PPGC 2017 - Day 1

Event Date/Time:

3/16/2017 6:30 AM to 3/16/2017 3:00 PM

Last Review:

3/18/2019 12:59 PM

Event Type:

Security:

  • Password or Payment Required

8:00am-8:10amWelcome and Opening Remarks
TRACK/THEMECARE OF THE NEONATE AND INFANT
Moderator: Phil Newcomm, MD
8:10am-8:35am

S101- HEALTHY BEGINNINGS: Infant Feeding & Optimal Nutrition of the Newborn Infant
Deborah Abel, PhD, RD

This session will cover all aspects of infant feedings in the healthy newborns including: Adequate amount, type of formulas, avoiding overfeeding, transitioning from breast milk to formula, timing of introduction to solids, etc.

8:35am-8:40amQ&A
8:40am-9:05am

S102- NEONATAL HYPOGLYCEMIA: What’s New?
Diva D. De Leon-Crutchlow, MD, MSCE

This session will cover on neonatal hypoglycemia. While hypoglycemia is common among neonates, treatment can be challenging if hypoglycemia persists beyond the first few days of life. This session discusses treatment options for both transient and persistent neonatal hypoglycemia. These treatment options include dextrose infusions, glucagon, glucocorticoids, diazoxide, octreotide, and nifedipine. A stepwise, practical approach to the management of these patients is will be discussed.

9:05am-9:10amQ&A
9:10am-9:35am

S103- NEONATAL JAUNDICE: The Good, The Bad, and The Worrisome
Magaly Diaz-Barbosa, MD

This session will discuss neonatal jaundice and its differential diagnosis from benign transient physiologic jaundice to the worrisome pathologic jaundice. This session will be based on the AAP guidelines and will focus on the role of the primary care provider in the identification and work-up.

9:35am-9:40amQ&A
TRACK/THEMECOMMON ISSUES IN PRIMARY CARE
9:40am-10:10am

S104- RECOGNIZING PEDIATRIC MALNUTRITION: No Longer Failure to Thrive
Jennifer Caceres, MS, RD, LDN

This session will focus on the identification standards for pediatric malnutrition (under nutrition) endorsement by the AAP.  The recommendation of use of z scores vs percentiles on growth charts will be discussed and practical application of the standards for the PMD will be reviewed.

10:10am-10:15amQ&A
10:15am-10:40amBREAK
 Moderator: Marisa Azaret, PsyD
10:40am-11:35am

S105, S106- FIRST DO NO HARM:  (Panel)- Unintended Consequences of Common Treatments

  • Safely Doing Less
  • Anesthesia consequences on the developing brain
  • Microbiome and hygiene hypothesis
  • PECARN Rules on when to CT closed head Trauma
  • Radiation exposure

Luis Mendoza, MD
Alejandro Diaz, MD
Mario Reyes, MD
Luisa Cervantes, MD

This session is framed as a panel discussion. It is slated for 60 minutes with 5 speakers 10 minutes each leaving 10 minutes for Q&A. The speakers would focus on common practices/ treatment strategies/ approaches which has emerging evidence of unintended immediate or future harm to the patient. The speakers should highlight the emerging evidence as parents might be coming to the pediatrician with questions. This will provide the pediatrician with ways to address these questions.

11:35am-11:40amQ&A
11:40am-12:25pm

Moderator: Nolan Altman, MD
P1- PLENARY SESSION – The Donald Altman Annual Lectureship – Imaging of Marrow Disorders in Children
Diego Jaramillo, MD, MPH

This session will cover the normal marrow transformation and the diagnostic imaging modalities for marrow disorders and the types of marrow disorders the MRI findings.

12:25pm-12:30pmQ&A

Faculty, Moderators, and Planners’ Disclosures

None of the PPGC speakers, moderators, and scientific planning committee members (and their spouse/partner) had any COIs or financial relationships to disclose in the past 12 months or plan to discuss unlabeled or investigational use of a drug, device, or product not approved in the U.S. except for the one(s) listed below:

Faculty, Moderator or PlannerPerson with COI or financial relationshipCompanyRole/RelationshipDiscussion of Investigational/Unlabeled Drugs or Devices
Ibrahim Amjad, MDSelfNoneNoneMixing of Enteral Formula
Richard Arboleda, MD, MPHSelfOtsukaConsulting FeeNone
Diva De Leon-Crutchlow, MDSelfXoma CorporationContracted Research

18FDOPA PET SCAN for identification of focal hyperinsulinism lesions (Investigational use)

Octreotide for treatment of Hyperinsulinism

SelfBiomarin PharmaceuticalsContracted Research
Self & Spouse/PartnerMerckOwnership Interest
Kelly Green Corkins, MS, RD, LDN, CNSDSelfNestle NutritionConsulting FeeNone
Vivian Hernandez-Trujillo, MDSelfMedaHonorariaNone
SelfBayerHonoraria & Consulting Fee, Claritin Council Member
SelfCSLContracted Research


All COIs have been resolved prior to the meeting. Faculty will disclose financial relationships or COIs to the audience verbally and/or with a slide at the beginning of their presentation.

NOTE! You must register in order to watch this event.
COMPATIBLE BROWSERS:
IE8, IE9, Firefox, Safari, Opera, Chrome, iOS, Android
© 2019 Hendrik Information Systems
Refund/Exchange and Privacy Policy